{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T19:50:49Z","timestamp":1670529049673},"reference-count":42,"publisher":"Cambridge University Press (CUP)","issue":"8","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":4846,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2001,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>In recent years, a number of antidepressants with varying degrees of selectivity for the noradrenergic neurotransmitter system have become available. However, these agents represent a pharmacologically heterogeneous group and differ in terms of their precise side-effect profile and, possibly, their clinical efficacy. Bupropion, which is thought to act on both the dopamine and norepinephrine (NE) systems, has not been widely used as an antidepressant and has more recently been licensed as adjunctive therapy for smoking cessation. The serotonin-NE reuptake inhibitors venlafaxine and nefazodone, the noradrenergic and specific serotonergic antide-pressant mirtazapine, and the selective NE reuptake inhibitor reboxetine (the only truly NE-selective agent available) have all demonstrated efficacy in the treatment of depressive disorders. Evidence is now emerging for their use in the treatment of anxiety and panic disorders. There is some suggestion of a role for noradrenergic agents in other disorders, including attention-deficit\/hyper-activity disorder and social phobia. The full range of disorders for which noradrenergic agents can be used remains to be seen and further research in this area is necessary.<\/jats:p>","DOI":"10.1017\/s1092852900001413","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T03:17:27Z","timestamp":1470107847000},"page":"710-713","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of Noradrenergic-Selective Agents in the Treatment of Neuropsychiatric Diseases"],"prefix":"10.1017","volume":"6","author":[{"given":"Siegfried F.","family":"Kasper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Resinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900001413_ref042","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200010000-00009"},{"key":"S1092852900001413_ref041","first-page":"36","article-title":"Mirtazapine: other indications","volume":"60","author":"Falkai","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"S1092852900001413_ref040","first-page":"54","article-title":"The use of newer antidepressants for panic disorder","volume":"58","author":"Gorman","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"S1092852900001413_ref027","first-page":"S9","article-title":"Reboxetine: additional benefits to the depressed patient","volume":"11","author":"Montgomery","year":"1997","journal-title":"J Psychopharmacol."},{"key":"S1092852900001413_ref013","doi-asserted-by":"publisher","DOI":"10.3109\/10401239409148989"},{"key":"S1092852900001413_ref003","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(98)00222-5"},{"key":"S1092852900001413_ref035","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199905001-00005"},{"key":"S1092852900001413_ref023","first-page":"53","article-title":"Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability and effects on sexual function and satisfaction","volume":"57","author":"Feiger","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"S1092852900001413_ref008","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1614.1999.00580.x"},{"key":"S1092852900001413_ref019","first-page":"511","article-title":"Venlafaxine and nefazodone, two pharmacologically distinct antidepressants","volume":"17","author":"Augustin","year":"1997","journal-title":"Pharmacotherapy"},{"key":"S1092852900001413_ref037","first-page":"9","article-title":"New indications for antidepressants","volume":"61","author":"Schatzberg","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"S1092852900001413_ref024","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n0508"},{"key":"S1092852900001413_ref009","doi-asserted-by":"publisher","DOI":"10.1177\/026988119701100118"},{"key":"S1092852900001413_ref012","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88317-4"},{"key":"S1092852900001413_ref020","first-page":"13","article-title":"Noradrenergic approaches to antidepressant therapy","volume":"61","author":"Gorman","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"S1092852900001413_ref025","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.1.4.771"},{"key":"S1092852900001413_ref034","first-page":"S33","article-title":"Reboxetine: a review of antidepressant tolerability","volume":"11","author":"Mucci","year":"1997","journal-title":"J Psychopharmacol."},{"key":"S1092852900001413_ref026","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199912010-00006"},{"key":"S1092852900001413_ref036","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199803000-00002"},{"key":"S1092852900001413_ref005","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6992.1433"},{"key":"S1092852900001413_ref001","volume-title":"The Global Burden of Disease","author":"Murray","year":"1998"},{"key":"S1092852900001413_ref032","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957040-00010"},{"key":"S1092852900001413_ref017","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)88287-9"},{"key":"S1092852900001413_ref018","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n1002"},{"key":"S1092852900001413_ref007","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2000.02605.x"},{"key":"S1092852900001413_ref010","first-page":"25","article-title":"Bupropion sustained release: a therapeutic overview","volume":"59","author":"Davidson","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"S1092852900001413_ref031","first-page":"245","article-title":"Reboxetine, a novel selective NRI, in the treatment of panic disorder [Abstract P.I.067]","volume":"10","author":"Versiani","year":"2000","journal-title":"Eur Neuropsychopharmacol."},{"key":"S1092852900001413_ref016","first-page":"99","article-title":"Once-daily extended release (XR) and venlafaxine immediate release in outpatients with major depression","volume":"14","author":"Cunningham","year":"1997","journal-title":"Ann Clin Psychiatry"},{"key":"S1092852900001413_ref039","first-page":"23","article-title":"Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder","volume":"60","author":"Sheehan","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"S1092852900001413_ref033","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19335"},{"key":"S1092852900001413_ref021","first-page":"450","article-title":"Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia","volume":"56","author":"Guelfi","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"S1092852900001413_ref038","first-page":"18","article-title":"Overview of antidepressants currently used to treat anxiety disorders","volume":"60","author":"Feighner","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"S1092852900001413_ref002","first-page":"4","article-title":"Mechanism of action of antidepressants medications","volume":"60","author":"Feighner","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"S1092852900001413_ref004","doi-asserted-by":"publisher","DOI":"10.1177\/026988119400800407"},{"key":"S1092852900001413_ref006","first-page":"623","volume-title":"J Clin Psychiatry.","volume":"60","author":"Schatzberg","year":"1999"},{"key":"S1092852900001413_ref011","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0511"},{"key":"S1092852900001413_ref014","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0309"},{"key":"S1092852900001413_ref015","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199549020-00010"},{"key":"S1092852900001413_ref022","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753040-00006"},{"key":"S1092852900001413_ref028","first-page":"S3","article-title":"Treatment benefits of reboxetine","volume":"3","author":"Kasper","year":"1999","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"key":"S1092852900001413_ref029","first-page":"S17","article-title":"Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning","volume":"11","author":"Dubini","year":"1997","journal-title":"J Psychopharmacol."},{"key":"S1092852900001413_ref030","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0610"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900001413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T23:30:13Z","timestamp":1557271813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900001413\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["S1092852900001413"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900001413","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}